CVS Health
CVS
$107.47
+0.91%
CVS Health is a diversified healthcare services company operating through retail pharmacies, pharmacy benefit management (PBM), and health insurance (Aetna) segments, with over 9,000 retail stores and approximately 27 million medical members. It is a vertically integrated healthcare giant, uniquely positioned at the intersection of pharmacy, insurance, and primary care (via Oak Street Health). The current investor narrative centers on a powerful turnaround driven by lower medical costs in its insurance unit, a favorable Medicare payment decision adding $13 billion in revenue, and raised full-year guidance, fueling a significant rally and debate over whether the stock's momentum can be sustained.…
CVS
CVS Health
$107.47
Related headlines
Investment Opinion: Should I buy CVS Today?
Rating: Buy. CVS Health is a compelling turnaround play with improving fundamentals, attractive forward valuation, and strong analyst support. The consensus Strong Buy and average target of $111.92 support a positive view, with the stock offering a favorable risk/reward at current levels.
Supporting evidence: Forward P/E of 12.8x is a 77% discount to the trailing P/E of 56.7x, implying massive earnings growth. Revenue grew 6.2% YoY to $100.4 billion in Q1 2026, and net margin improved to 2.9% from 1.9% a year ago. Free cash flow of $7.4 billion TTM provides financial flexibility. The dividend yield of 3.4% adds income, and the stock has outperformed the S&P 500 by 51.4% over the past year.
Risks & Conditions: The main risks are a reversal in medical cost trends, integration issues with Oak Street Health, and regulatory changes. This Buy would downgrade to Hold if the forward P/E expands above 15x without earnings confirmation, or if revenue growth decelerates below 5%. Upgrade to Strong Buy if the stock pulls back to $95-100 while fundamentals remain intact. Overall, CVS appears undervalued on a forward basis relative to its history and peers, but the trailing metrics caution that the recovery is not yet fully proven.
Sign up to view all
CVS 12-Month Price Forecast
CVS Health is positioned for a continued rally, driven by a fundamental turnaround in its insurance segment and attractive forward valuation. The base case of a gradual recovery to the analyst average target is most likely, but the bull case has meaningful upside if medical costs remain favorable. The main risk is a reversal in cost trends, which could trigger a sharp re-rating. Overall, the risk/reward is favorable, and the stock is well-suited for investors seeking a value-oriented healthcare play with income. Upgrade to higher confidence if Q2 2026 earnings confirm margin expansion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS Health's 12-month outlook, with a consensus price target around $111.92 and implied upside of +4.1% versus the current price.
Average Target
$111.92
0 analysts
Implied Upside
+4.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $148
Analyst target range
CVS is covered by 26 analysts, with a consensus recommendation of 'Strong Buy' (mean score 1.5 out of 5). The average target price is $111.92, implying approximately 4.1% upside from the current price of $107.47. The distribution leans heavily bullish, with no sell ratings reported. Recent ratings from Wells Fargo, RBC Capital, and BofA Securities are all positive, reinforcing the bullish consensus.
The target range spans from $79.00 (low) to $148.00 (high), a wide spread of $69, indicating significant uncertainty about the pace of the turnaround. The high target of $148 assumes continued margin expansion, successful integration of Oak Street Health, and sustained low medical costs. The low target of $79 implies a scenario where the insurance rebound fades or regulatory pressures emerge. The wide spread suggests high conviction in the direction but low confidence in the magnitude, typical of a turnaround story.
Drowning in data?
Find the real signal!
Bulls vs Bears: CVS Investment Factors
CVS Health presents a compelling turnaround story with strong momentum, supported by a lower medical cost ratio, favorable Medicare payments, and raised guidance. The forward P/E of 12.8x is attractive, but the trailing P/E of 56.7x warns of earnings volatility. The bull case is currently stronger, driven by improving fundamentals and analyst support, but the wide target range and leverage risks temper conviction. The key tension is whether the earnings rebound is sustainable: if medical costs remain low and guidance is met, the stock could re-rate higher; if not, the high trailing multiple leaves room for significant downside.
Bullish
- Strong earnings rebound and raised guidance: Q1 2026 EPS of $2.31 beat expectations, and the company raised full-year guidance, driven by a lower medical cost ratio. This signals a sustainable turnaround in the insurance segment.
- Favorable Medicare payment decision: A CMS ruling added $13 billion in revenue visibility, boosting CVS's profit outlook and reducing regulatory uncertainty. This directly benefits the Aetna segment.
- Attractive forward valuation: With a forward P/E of 12.8x, CVS trades at a discount to its historical average and many managed care peers. This implies significant upside if earnings materialize as expected.
- Strong free cash flow generation: TTM free cash flow of $7.4 billion provides ample capacity for debt reduction, dividends, and share buybacks. The dividend yield of 3.4% adds income appeal.
Bearish
- High trailing P/E and earnings volatility: The trailing P/E of 56.7x is extremely elevated, reflecting depressed past earnings. If the earnings rebound falters, the stock could re-rate sharply lower.
- Liquidity and leverage concerns: The current ratio of 0.84 indicates potential short-term liquidity pressure, and debt-to-equity of 1.24 shows moderate leverage. Rising interest rates could increase debt service costs.
- Wide analyst target range: Targets range from $79 to $148, a spread of $69, indicating high uncertainty. The low target implies 26.5% downside from current levels, highlighting significant risk.
- Margin pressure from retail and PBM: Gross margin of 15.6% and operating margin of 4.7% are relatively thin. Reimbursement pressures in pharmacy and PBM could compress margins further.
CVS Technical Analysis
CVS is in a sustained uptrend, with the stock up 69.8% over the past year, significantly outperforming the S&P 500's 18.4% gain. The current price of $107.47 sits at 98.6% of its 52-week range ($58.50–$108.96), indicating the stock is near its highs, reflecting strong momentum but also potential overextension. The 1-year price change of +69.8% and the 52-week high proximity suggest a powerful bullish trend, though caution is warranted near resistance.
Short-term momentum is accelerating: the 1-month price change is +8.4% and the 3-month change is +39.0%, both outpacing the S&P 500's 0.3% and 4.7% gains, respectively. The 1-month trend (+8.4%) aligns with the longer-term uptrend, confirming strong near-term buying pressure. The relative strength index (not provided) would likely be elevated, but the consistent upward price action and volume (6.6 million shares) support the bullish case.
The 52-week low of $58.50 provides key support, while the 52-week high of $108.96 is immediate resistance. A breakout above $108.96 would signal further upside, targeting new highs. The stock's beta of 0.60 indicates it is 40% less volatile than the market, making it a lower-risk way to participate in the healthcare rally. A breakdown below $100 (recent consolidation area) could signal a pullback, but the trend remains firmly bullish.
Beta
0.60
0.60x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$59-$109
Price range past year
Annual Return
+69.8%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | +8.4% | -0.5% |
| 3m | +39.0% | +4.9% |
| 6m | +36.7% | +9.7% |
| 1y | +69.8% | +18.4% |
| ytd | +34.1% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
CVS's revenue trajectory is growing, with Q1 2026 revenue of $100.4 billion, up 6.2% year-over-year from $94.6 billion in Q1 2025. The multi-quarter trend shows steady growth: Q4 2025 revenue was $105.7 billion, Q3 2025 was $102.9 billion, and Q2 2025 was $98.9 billion. Revenue segments are driven by Pharmacy Revenue ($56.9B) and Premiums ($33.8B), with Front Store Revenue ($5.3B) adding stability. The 6.2% YoY growth indicates a healthy expansion, supported by the insurance segment's rebound.
The company is profitable, with Q1 2026 net income of $2.94 billion and gross margin of 15.6%. Net margin improved to 2.9% in Q1 2026 from 1.9% in Q1 2025, while operating margin rose to 4.7% from 3.6% a year ago. The trailing twelve-month free cash flow is $7.4 billion, demonstrating strong cash generation. Margins are expanding, driven by lower medical costs and operational efficiency, which is positive for the investment case.
CVS has a debt-to-equity ratio of 1.24, indicating moderate leverage, but free cash flow of $7.4 billion TTM provides ample coverage. The current ratio of 0.84 suggests some liquidity pressure, but operating cash flow of $4.2 billion in Q1 2026 comfortably covers capital expenditures of $0.85 billion. ROE is 2.4%, which is low but improving from negative levels in prior quarters. The balance sheet is manageable, with the company generating sufficient cash to fund operations and reduce debt.
Quarterly Revenue
$100.4B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
15.6%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Since net income is positive ($2.94 billion in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 56.7x, while the forward P/E is 12.8x, a massive gap that implies the market expects earnings to surge in the coming year. This forward multiple is much more reasonable and reflects the anticipated recovery in profitability after a weak 2025.
Compared to the industry (Medical - Healthcare Plans), CVS's forward P/E of 12.8x is at a discount to the sector average (not provided, but typically higher for managed care). The P/S ratio of 0.25x is extremely low, suggesting the market is pricing in low margins. The EV/EBITDA of 18.8x is elevated, but the forward P/E discount indicates value relative to peers if earnings materialize.
Historically, CVS's trailing P/E of 56.7x is near the top of its 5-year range (which has fluctuated between 8x and 60x). However, the forward P/E of 12.8x is near the lower end of its historical band, suggesting the market is pricing in a sharp earnings rebound. The current valuation reflects optimism about the turnaround, but the trailing multiple warns of potential overvaluation if earnings disappoint.
PE
56.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CVS's trailing P/E of 56.7x is extremely high, reflecting a sharp earnings recovery that may not materialize if medical costs rise again. The current ratio of 0.84 indicates potential liquidity pressure, and debt-to-equity of 1.24 shows moderate leverage, with interest expense of $774 million in Q1 2026. Free cash flow of $7.4 billion TTM provides coverage, but any earnings miss could strain debt servicing. Revenue concentration in pharmacy ($56.9B) and premiums ($33.8B) exposes the company to reimbursement cuts and utilization spikes.
Market & Competitive Risks: The stock's beta of 0.60 suggests lower market correlation, but valuation compression is a risk if the forward P/E of 12.8x expands to match peers. Competitive threats from UnitedHealth and Humana in Medicare Advantage, and from Amazon in pharmacy, could pressure margins. Regulatory risk from drug pricing reforms or changes to Medicare Advantage payment rates could impact revenue. Recent news highlights a favorable CMS decision, but future policy shifts remain uncertain.
Worst-Case Scenario: If medical costs spike, guidance is missed, and the earnings rebound stalls, the stock could fall to the analyst low target of $79, representing a 26.5% decline from the current price of $107.47. The 52-week low of $58.50 would imply a 45.6% drop, though this is less likely given improved fundamentals. In this scenario, the trailing P/E would remain elevated, and investor sentiment would turn negative, potentially triggering further downgrades.
FAQ
The primary risk is a reversal in medical cost trends, which could derail the earnings recovery and cause the stock to re-rate lower. Financial risks include a current ratio of 0.84, indicating potential liquidity pressure, and debt-to-equity of 1.24, which could become problematic if interest rates rise. Competitive risks from UnitedHealth, Humana, and Amazon in pharmacy could pressure margins. Regulatory risks include changes to Medicare Advantage payments or drug pricing reforms. The most severe risk is a guidance cut, which could send the stock to the analyst low target of $79, a 26.5% decline from current levels.
The 12-month outlook is positive, with a base case target of $105-$120 (50% probability), aligning with the analyst average of $111.92. The bull case (30% probability) targets $120-$148, driven by sustained low medical costs and successful integration of Oak Street Health. The bear case (20% probability) sees the stock falling to $79-$95 if medical costs spike or guidance is cut. The most likely scenario is a gradual recovery, with the stock trading near current levels or slightly higher. Key assumptions include stable medical cost ratios and continued revenue growth of 5-7%.
CVS appears undervalued on a forward basis, with a forward P/E of 12.8x, which is a discount to its historical average and many managed care peers. However, the trailing P/E of 56.7x is extremely high, reflecting depressed past earnings. The P/S ratio of 0.25x is also low, suggesting the market is pricing in thin margins. Overall, the valuation implies that the market expects a sharp earnings recovery; if that materializes, the stock is cheap. If not, the trailing multiple suggests overvaluation. The EV/EBITDA of 18.8x is elevated, but the forward P/E discount makes the stock attractive for value investors.
CVS Health offers a compelling risk/reward at current levels, with a forward P/E of 12.8x that is well below its trailing multiple of 56.7x, implying a strong earnings rebound. The consensus analyst target of $111.92 suggests 4.1% upside, and the stock has strong momentum, up 69.8% over the past year. However, the wide target range ($79-$148) indicates uncertainty, and the trailing P/E warns of potential overvaluation if earnings disappoint. For investors with a medium-term horizon who believe in the turnaround story, CVS is a good buy, especially on any pullback. Income-focused investors will appreciate the 3.4% dividend yield.
CVS is best suited for a medium- to long-term investment horizon of 12-24 months, as the turnaround story needs time to play out. The low beta of 0.60 makes it less volatile than the market, appealing for long-term holders seeking lower risk. The 3.4% dividend yield provides income while waiting for capital appreciation. Short-term traders may find the stock near its 52-week high, limiting upside, but the strong momentum could continue. A minimum holding period of 12 months is recommended to allow the earnings recovery to materialize and reduce the impact of short-term volatility.
